← boardnext 2030-06
PLRX
Pliant Therapeutics, Inc.distress 1/10 · well-funded / low risk$1.08-2%today-42% from 52w high
Respiratory 1
Lead: Advanced or Metastatic Solid Tumor
Revenue
pre-revenue
Liquidity
$171M
Runway
1.7 yrs
Shares 1y
+1%
Price & events
-16.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.8%
1D
-2.7%
1W
-6.9%
1M
-14.3%
3M
-16.9%
6M
-31.6%
1Y
-91.6%
2Y
-95.7%
5Y
-95.6%
All
Overview
- Market Cap
- $66.87M
- Enterprise Value
- $44.68M
- Volume
- 76.39K
- 52 Week Range
- $1.07 – $1.87
- Total Shares
- 61.92M
- Float Shares
- 57.08M
- Short %
- 4.27%
- % Held by Insiders
- 2.23%
- % Held by Institutions
- 82.06%
- RVOL
- 0.13x
- Beta
- 1.22
Pipeline stages · 1 programs
PLN-101095, Pembrolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2030-06 Estimated 50% readout ~2030-07-01 | Phase 1 | PLN-101095, Pembrolizumab | Advanced or Metastatic Solid Tumor | — | recruiting |
| 2025-04-04 | Phase 2 | PLN-74809 | Idiopathic Pulmonary Fibrosis | 320 | terminated |
Catalyst news & presentations · 3
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025-02-07clinical holdbexotegrast · voluntarily paused enrollment and dosing in BEACON-IPF Phase 2b trialSEC 8-K
- 2024-07-15fda agreementbexotegrast · FDA supportive of a 52-week, dose-ranging Phase 2b trial employing non-invasive endpointsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
hold · target $3 (+131% upside) · 2 analysts
- 2026-03-13Canaccord GenuityHold
- 2026-03-12Piper SandlerOverweight
- 2025-11-07RBC CapitalSector Perform
- 2025-10-10JP MorganNeutral → Underweight
- 2025-08-08Piper SandlerOverweight
- 2025-03-18HC Wainwright & Co.Neutral
Competitors — Advanced or Metastatic Solid Tumor
- AMGNAMGEN INC$195.4B · D3
- GILDGILEAD SCIENCES, INC.$159.5B · D2
- TKPHFTAKEDA PHARMACEUTICAL CO LTD$53.7B · D1
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- ERASErasca, Inc.$5.9B · D4
- AVBPArriVent BioPharma, Inc.$1.4B · D1
- CHRSCoherus Oncology, Inc.$218M · D7
- IPHYFInnate Pharma SA$155M · D2
- HOWLWerewolf Therapeutics, Inc.$18M · D5
- NXTCNextCure, Inc.$16M · D9
Recent news
- 2026-07-13Pliant Therapeutics adds independent directors to strengthen R&D - TipRanks
- 2026-07-13Form 4 Pliant Therapeutics Inc For: 13 July By Investing.com - Investing.com Canada
- 2026-07-13[8-K] PLIANT THERAPEUTICS, INC. Reports Material Event - Stock Titan
- 2026-07-13Pliant Therapeutics adds two directors with oncology expertise - Investing.com UK
- 2026-07-13Pliant Therapeutics adds two directors with oncology expertise - Investing.com
- 2026-07-13Pliant Therapeutics adds two directors with oncology expertise By Investing.com - Investing.com Canada
- 2026-07-13Two cancer drug veterans join Pliant Therapeutics’ board to guide PLN-101095 - Stock Titan
- 2026-07-13Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.